Drug Trial Radar · NCT02247804
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
594
Actual
Start
Dec 15, 2014
Primary completion
Feb 19, 2018
Study completion Jul 19, 2019
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Conditions
- Glaucoma, Open-Angle
- Ocular Hypertension
Interventions
Bimatoprost SRDrug
Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
Active Comparator: Timolol 0.5%Drug
Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Sham: Applicator Without NeedleOther
Sham administered on Day 1, Week 16, and Week 32.
Timolol Vehicle (placebo)Drug
Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2)Time frame: Baseline (Hours 0 and 2) to Week 12 (Hours 0 and 2)
- IOP in the Study Eye at Week 2 (Hour 0)Time frame: Week 2 (Hour 0)
- IOP in the Study Eye at Week 2 (Hour 2)Time frame: Week 2 (Hour 2)
- IOP in the Study Eye at Week 6 (Hour 0)Time frame: Week 6 (Hour 0)
- IOP in the Study Eye at Week 6 (Hour 2)Time frame: Week 6 (Hour 2)
- IOP in the Study Eye at Week 12 (Hour 0)Time frame: Week 12 (Hour 0)
- IOP in the Study Eye at Week 12 (Hour 2)Time frame: Week 12 (Hour 2)
Locations
106 sites in 14 countries. Site status is shown where the registry gives one.
Arizona Glaucoma Specialists
Phoenix, Arizona
Lugene Eye Institute
Glendale, California
Lakeside Vision Center
Irvine, California
Hamilton Glaucoma Center, Shiley Eye Center UCSD
La Jolla, California
Atlantis Eye Care
Long Beach, California
Glaucoma Institute of Beverly Hills
Los Angeles, California
Montebello Medical Eye Center Inc.
Montebello, California
Stanford University
Palo Alto, California
Foothill Eye Institute
Pasadena, California
Martel Eye Medical Group
Rancho Cordova, California
Grutzmacher, Lewis and Sierra, Inc.
Sacramento, California
Pacific Eye Associates
San Francisco, California
Eye Associates of Colorado Springs
Colorado Springs, Colorado
Palm Beach Eye Center, INC
Atlantis, Florida
Nature Coast Clinical Research
Crystal River, Florida
Levenson Eye Associates
Jacksonville, Florida
East Florida Eye Institute
Stuart, Florida
International Research Center
Tampa, Florida
Coastal Research Associates, LLC
Roswell, Georgia
Chicago Eye Specialists
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
Heart of America Eye Care PA
Shawnee Mission, Kansas
Tulane Medical Center
New Orleans, Louisiana
Eye Doctors of Washington
Chevy Chase, Maryland
MedRACS, LLC
Quincy, Massachusetts
Ocular Immunology and Uveitis Foundation
Waltham, Massachusetts
University of Michigan
Ann Arbor, Michigan
Minnesota Eye Constultants, P.A.
Bloomington, Minnesota
Lifelong Vision Foundation
Chesterfield, Missouri
Moyes Eye Center, PC
Kansas City, Missouri
Northern New Jersey Eye Institute P.A.
South Orange, New Jersey
Eyecare Ophthalmology Associates, PC
Bethpage, New York
New York Eye and Ear Infirmary of Mount Sinai
New York, New York
Rochester Ophthalmological Group PC
Rochester, New York
2000 North Village Avenue
Rockville Centre, New York
Glaucoma Consultants of the Capital Region
Slingerlands, New York
Montefiore Medical Center
The Bronx, New York
8 Medical Park Drive
Asheville, North Carolina
Albemarle Clinical Trials, LLC
Elizabeth City, North Carolina
University Hospitals of Cleveland
Cleveland, Ohio
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.